QHSLab, Inc. (USAQ)
Healthcare · OQB
Price as at 1 Oct 2026, 03:21 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
QHSLab, Inc. trades at $0.32, which is 141% below the $0.77 our fair value estimate puts on the business. On that measure alone it screens as undervalued, though a valuation model is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 74 out of 100, which is a wide moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 11.6 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
About QHSLab, Inc.
QHSLab, Inc., a medical device technology and software-as-a-service (SaaS) company, provides tools to evaluate and treat chronic disease and preventive care through reimbursable procedures. The company focuses on value-based healthcare, informatics, and algorithmic personalized medicine, including digital therapeutics, behavior based remote patient monitoring, and chronic care and preventive medicine. Its digital healthcare and clinical decision support and point of care solutions also support non face to face remote patient and therapeutic monitoring, address chronic care, and preventive medicine. The company provides quality health system lab expert system (QHSLab), designed to function as an extension of a medical practice's existing clinical workflow that supports structured screening, automated documentation, and digital follow-up while minimizing disruption to physicians and staff; and AllergiEnd, a diagnostic and allergen immunotherapy system for the busy non-allergist in a primary care setting. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. The company was incorporated in 1983 and is based in West Palm Beach, Florida.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
USAQ passes 6 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
USAQ peers
The largest companies in the same industry (Medical Devices), then in the same sector.
- PHG Koninklijke Philips N.V.
- PEN Penumbra, Inc.
- GMED Globus Medical, Inc.
- BIO Bio-Rad Laboratories, Inc.
- LIVN LivaNova PLC
- IRTC iRhythm Holdings, Inc.
- TMDX TransMedics Group, Inc.
- NEOG Neogen Corporation
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is QHSLab, Inc. (USAQ) undervalued?
Against our fair value estimate of $0.77, USAQ at $0.32 is 141% below fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
What is USAQ's P/E ratio?
USAQ trades at 11.6 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Where does SteadyShares get its USAQ data?
Fundamentals for USAQ come from company filings and exchange data, as listed on OQB; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 03:21 UTC and is delayed. Our data quality score for this company is 92/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for USAQ, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.